| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Institute of Pathology*
and Institute of
Experimental Internal Medicine,
Otto-von-Guericke-University of Magdeburg, Magdeburg, Germany; the
Biotechnology Center of Oslo,
University of
Oslo, Oslo, Norway; and the Department of Infectious and Tropical
Diseases,
Immunology Unit, London School of
Hygiene and Tropical Medicine, London, England
We recently demonstrated the presence of matrix metalloproteinases (MMPs)-1, -2, and -3 in AA amyloid deposits, which lead us to speculate that MMPs may participate in amyloidogenesis by either processing the precursor protein, or by degrading the amyloid deposits. Here we investigated this theory by determining the ability of MMP-1, -2, and -3 to degrade human acute-phase serum amyloid A (SAA) and human AA amyloid fibril proteins (AFPs). The following in vitro degradation experiments were performed: using either recombinant MMP-1, -2, or -3 and SAA as a substrate; using either recombinant MMP-1, -2, or -3 and AFP as a substrate; and using THP-1 cells as the protease source and AFP as the substrate. All three MMPs were able to cleave SAA and AFP within the region spanning residues 51 to 57. The following cleavage sites were identified: at 57 to 58 for MMP-1; at 7 to 8 and 51 to 52 for MMP-2; at 7 to 8, 16 to 17, 23 to 24, 51 to 52, 55 to 56, 56 to 57, and 57 to 58 for MMP-3. Cell culture experiments showed that THP-1 cells were able to degrade AFPs. Degradation was significantly delayed after addition of a general metalloproteinase inhibitor (o-phenanthroline) to dextran sulfate-stimulated cells. This is the first study to show that human SAAs and AFPs are susceptible to proteolytic cleavage by MMPs. Immunocytochemistry and electron microscopy showed that degradation takes place in the pericellular or extracellular compartment.
This article has been cited by other articles:
 |
|
 |
|
  G. S. Butler, R. A. Dean, E. M. Tam, and C. M. Overall Pharmacoproteomics of a Metalloproteinase Hydroxamate Inhibitor in Breast Cancer Cells: Dynamics of Membrane Type 1 Matrix Metalloproteinase-Mediated Membrane Protein Shedding Mol. Cell. Biol., August 1, 2008; 28(15): 4896 - 4914. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Herczenik and M. F. B. G. Gebbink Molecular and cellular aspects of protein misfolding and disease FASEB J, July 1, 2008; 22(7): 2115 - 2133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. de Seny, M. Fillet, C. Ribbens, R. Maree, M.-A. Meuwis, L. Lutteri, J.-P. Chapelle, L. Wehenkel, E. Louis, M.-P. Merville, et al. Monomeric Calgranulins Measured by SELDI-TOF Mass Spectrometry and Calprotectin Measured by ELISA as Biomarkers in Arthritis Clin. Chem., June 1, 2008; 54(6): 1066 - 1075. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. White, T. Du, K. M. Laughton, I. Volitakis, R. A. Sharples, M. E. Xilinas, D. E. Hoke, R. M. D. Holsinger, G. Evin, R. A. Cherny, et al. Degradation of the Alzheimer Disease Amyloid beta-Peptide by Metal-dependent Up-regulation of Metalloprotease Activity J. Biol. Chem., June 30, 2006; 281(26): 17670 - 17680. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Cardoso and M. J. Saraiva Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model FASEB J, February 1, 2006; 20(2): 234 - 239. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Rocken, R Menard, F Buhling, S Vockler, J Raynes, B Stix, S Kruger, A Roessner, and T Kahne Proteolysis of serum amyloid A and AA amyloid proteins by cysteine proteases: cathepsin B generates AA amyloid proteins and cathepsin L may prevent their formation Ann Rheum Dis, June 1, 2005; 64(6): 808 - 815. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.M.P.M. Ruwanpura, K. Noguchi, and I. Ishikawa Prostaglandin E2 Regulates Interleukin-1{beta}-induced Matrix Metalloproteinase-3 Production in Human Gingival Fibroblasts J. Dent. Res., March 1, 2004; 83(3): 260 - 265. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Merlini and V. Bellotti Molecular Mechanisms of Amyloidosis N. Engl. J. Med., August 7, 2003; 349(6): 583 - 596. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Chen, D. Li, T. Saldeen, and J. L. Mehta TGF-beta 1 attenuates myocardial ischemia-reperfusion injury via inhibition of upregulation of MMP-1 Am J Physiol Heart Circ Physiol, May 1, 2003; 284(5): H1612 - H1617. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Rocken, R. Kientsch-Engel, S. Mansfeld, B. Stix, K. Stubenrauch, B. Weigle, F. Buhling, M. Schwan, and W. Saeger Advanced Glycation End Products and Receptor for Advanced Glycation End Products in AA Amyloidosis Am. J. Pathol., April 1, 2003; 162(4): 1213 - 1220. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
